LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

H.S Rugo,A Bardia,F Marmé,J Cortés,P Schmid,D Loirat,O Tredan,E.M Ciruelos,F Dalenc,P Gomez Pardo,K Jhaveri,R.J Delaney,T Valdez,H Wang,W Verret,S.M Tolaney

doi:10.1016/j.annonc.2022.08.012

LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

H.S Rugo, A Bardia + Show 14 more

Open Access

https://doi.org/10.1016/j.annonc.2022.08.012

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
Citations: 32	License type: publisher-specific-oa

Affiliation: University of California, San Francisco, Massachusetts General Hospital, Heidelberg University, European University of Madrid, Queen Mary University of London, Institute Curie, Centre Léon Bérard, Hospital Universitario 12 De Octubre, Institut Claudius Regaud, Vall d'Hebron Hospital Universitari, Memorial Sloan Kettering Cancer Center, Gilead Sciences (United States), Dana-Farber Cancer Institute, Harvard University

#Treatment Of Physician's Choice #Sacituzumab Govitecan + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Pts with HR+/HER2- mBC are treated with endocrine-based therapy (ET), followed by single-agent chemotherapy (CT), with increasingly shorter durations of benefit. SG is an anti–Trop-2 antibody-drug conjugate approved for triple-negative mBC with ≥2 prior therapies (≥1 in the metastatic setting). In TROPiCS-02 (NCT03901339), SG showed significant progression-free survival (PFS) benefit vs TPC in ET resistant HR+/HER2- mBC (HR, 0.66; P<0.001; median 5.5 vs 4.0 mo; Rugo, et al. ASCO 2022). Here, we report the planned TROPiCS-02 OS 2nd interim analysis.

Full Text